Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04861987 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors
A Phase 1 study of Advanced Cancer and Refractory Cancer, sponsored by Processa Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 6
- Study locations
NCT04861987 is a Phase 1 study of Advanced Cancer and Refractory Cancer that has completed, run by Processa Pharmaceuticals. The registered enrollment target is 23 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (91% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT04861987, a Phase 1 study of Advanced Cancer and Refractory Cancer, has completed, sponsored by Processa Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study is an open label, multicenter study in patients who have advanced, relapsed refractory GI cancer or are not relapsed/refractory but are intolerant to other therapies who, in the judgment of investigators, are candidates for fluoropyrimidine monotherapy.
Conditions Studied
Interventions
- DRUG PCS6422 and capecitabine
Study Locations (6)
Nebraska
- Processa Clinical Site - Omaha
New Jersey
- Processa Clinical Site - New Brunswick
New Mexico
- Processa Clinical Site - Santa Fe
New York
- Processa Clinical Site - New York
Ohio
- Processa Clinical Site - Cleveland
Virginia
- Processa Clinical Site - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2021-06-18 |
| Est. Completion | 2024-09-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04861987
The ClinicalTrials.gov registry entry for NCT04861987 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Processa Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which PCS6422 and capecitabine is the first listed.
NCT04861987 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Nebraska, New Jersey, New Mexico.
Frequently Asked Questions
What is clinical trial NCT04861987 about?
NCT04861987 is a clinical study titled "A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors". This study is an open label, multicenter study in patients who have advanced, relapsed refractory GI cancer or are not relapsed/refractory but are intolerant to other therapies who, in the judgment of investigators, are candidates for fluoropyrimidine monotherapy.
What is the current status of trial NCT04861987?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2021-06-18. Estimated completion is 2024-09-09.
What conditions does trial NCT04861987 study?
This clinical trial studies the following conditions: Advanced Cancer, Refractory Cancer, Tumor Gastric.
What interventions are being tested in trial NCT04861987?
The interventions under investigation include: PCS6422 and capecitabine (DRUG).
Who is sponsoring clinical trial NCT04861987?
This trial is sponsored by Processa Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04861987 being conducted?
This trial has 6 study locations across Nebraska, New Jersey, New Mexico, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.